Study to evaluate the safety and efficacy of PAZ320 when added to oral agents or insulin in patients with type 2 diabetes mellitus
Phase of Trial: Phase II
Latest Information Update: 22 Sep 2014
At a glance
- Drugs BTI 320 (Primary) ; Antihyperglycaemics; Insulin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Boston Therapeutics
- 22 Sep 2014 Results published in a Boston Therapeutics media release.
- 04 Sep 2013 Results have been published in the July/August issue of Endocrine Practice according to a Boston Therapeutics media release. Results were also summarised in the media release.
- 26 Feb 2013 Results have been published electronically in an abstract ahead of print in Endocrine Practice according to a Boston Therapeutics media release. The full article is expected to be published in the July/August issue of the journal.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History